Cost-effectiveness of Apixaban Compared With Edoxaban for Stroke Prevention in Nonvalvular Atrial Fi...
Cost-effectiveness of Apixaban Compared With Edoxaban for Stroke Prevention in Nonvalvular Atrial Fibrillation
About this item
Full title
Author / Creator
Publisher
United States: Elsevier Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: Elsevier Inc
Subjects
More information
Scope and Contents
Contents
Abstract Purpose The purpose of this analysis was to assess the cost-effectiveness of apixaban 5 mg BID versus high- and low-dose edoxaban (60 mg and 30 mg once daily) as intended starting dose strategies for stroke prevention in patients from a UK National Health Service perspective. Methods A previously developed and validated Markov model was ad...
Alternative Titles
Full title
Cost-effectiveness of Apixaban Compared With Edoxaban for Stroke Prevention in Nonvalvular Atrial Fibrillation
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1736680756
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1736680756
Other Identifiers
ISSN
0149-2918
E-ISSN
1879-114X
DOI
10.1016/j.clinthera.2015.09.005
